Pharmaceuticals, Biotechnology and Life Sciences
Valneva SE and Pfizer Inc. have reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has reported €73 million net loss in its audited consolidated financial results for the year ending December 31, 2021 and provided corporate updates.
Valneva SE has provided an update on the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Valneva SE has announced successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553.
National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain has granted emergency use authorization for Valneva’s inactivated, adjuvanted COVID-19…
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, has announced that the Committee for Medicinal Products for…
Valneva’s subsidiary Valneva Scotland has been awarded research and development funding of up to £20 million by Scottish Enterprise. The…
Valneva has given Merck in United States and Canada rights to use its EB66 technology to research new veterinary vaccines.
French vaccines developer Valneva has closed the share issuance in connection with MVM Life Science Partners LLP`s investment in the…